Clonal Architecture of ASXL1-mutated Myelofibrosis
Recruiting
N/A
Interventional Study
Myelofibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 50 (estimated)
- Sponsor
- University Hospital, Angers · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Prospective study to decipher the clonal architecture of ASXL1-mutated primary and secondary myelofibrosis and its impact on prognosis
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults (age ≥18 years),
* Affiliated to the national social security system,
* ASXL1 mutated primary or secondary myelofibrosis,
* Signed the consent to participate in the study,
* Included, or consenting to be included, in the national clinical-biological database of France I…
Contacts